|
|
BY OUR PHARMA CORRESPONDENT
4 September, 2005: Generic version of the anti-cholesterol drug Questran has been granted marketing approval by the U.S. Food and Drug Administration.
The federal regulator has given final approval for for cholestyramine for oral suspension, 4g resin/9g powder and cholestyramine for oral suspension, (light), 4g resin/5g powder, Par Pharmaceutical Companies, Inc, maker of the generic, announced in a press release.
Cholestyramine is the generic version of Bristol-Myers Squibb Company's Questran Powder and Questran Light Powder for Oral Suspension, and is used for the treatment of primary hypercholesterolemia.
U.S. sales of cholestyramine products are approximately $50 million, according to IMS health. Cholestyramine for oral suspension (regular and light), will be available in multiple-dose containers providing 4g resin/scoopful and single-use packets containing 4g resin/packet.
According to the release, Par will begin shipping the products shortly.
Par Pharmaceutical Companies, Inc. develops, manufactures and markets generic pharmaceuticals through its principal subsidiary, Par Pharmaceutical, Inc. The company is also developing an additional line of branded pharmaceutical products, the first of which is Megace ES, for specialty markets. Par currently manufactures, markets or licenses more than 90 prescription drugs.
BY OUR PHARMA CORRESPONDENT
|
